Side Effects and Safety Signals to Monitor The absence of large-scale human RCTs means the safety profile of BPC-157 is incomplete
doi: 10.3389/fphar.2024.1323083 Received 17 October 2023 Accepted 02 January 2024 Published 16 January 2024 Volume 15 - 2024 Edited by Pranav Kumar Prabhakar, Lovely Professional University, India Reviewed by Yong Zhi Lun, Putian University, China Updates Copyright 2024 Buczyska, Kociuszko, Krtowski and Popawska-Kita
Moreover, a recent SURPASS-3 MRI substudy has shown that tirzepatide may be more effective in reducing liver fat than insulin degludec [93]
However, glucagon agonism also comes with its own side effects and considerations
For example, combinations of GLP-1/glucagon RA achieve more liver fat content reduction in people with MASLD compared to GLP-1 RA alone despite similar WL, likely due to the direct effect of glucagon on hepatic lipid oxidation [79]